FDA Focused on Early Stage Disease Detection

SUNNYVALE, CA--(Marketwire - November 12, 2009) - Arrayit Corporation (OTCBB: ARYC) announced today that the company’s majority owned subsidiary, Arrayit Diagnostics, Inc., will launch the most intensive marketing campaign in the company’s thirteen-year history. The company is currently developing several diagnostic tests that will provide early detection for cancers, neurodegenerative diseases and other disease states. By conclusively identifying the genomic and proteomic biomarkers for specific diseases, these tests will enable early stage diagnosis, leading to life saving and cost saving treatments. Arrayit Diagnostics will promote the commercialization of these tests from its international headquarters in Houston, Texas.

Arrayit Diagnostics has named John Howell as its CEO and President. “Arrayit Diagnostics has the potential to globally renovate the health care sector, allowing the diagnostics community to rethink the way diseases are diagnosed and treated. Rather than reacting after symptoms have already appeared, our tests will allow early detection, enabling earlier intervention and treatment for patients, reducing costs compared to later stage treatments, and potentially saving lives,” stated John Howell, who brings his extensive experience serving as a senior executive of public corporations to the company.

“We are very pleased to launch Arrayit Diagnostics. It is an endeavor we have been striving to achieve for some time. Arrayit Diagnostics will utilize the strong foundation built by Arrayit Corporation, and we have the utmost confidence in Mr. Howell to see that Arrayit Diagnostics succeeds,” stated Rene Schena, CEO of Arrayit Corp.

Utilizing a talented sales team and its massive network of 41 international life science and diagnostics distributors located in 38 countries, Arrayit will use this opportunity to expand its worldwide customer base of 10,000 research labs to become a significant global diagnostics company.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 10,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company’s business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company’s Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second quarter ended June 30, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2009.